Free tool
FAERS Monitor: Omlonti
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215092 or its brand name (Omlonti, Omidenepag Isopropyl). Reports on generic versions are filed under their own applications.
Reports
66
Serious
64
97% of reports
Hospitalization
10
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cataract20
- contraindicated product administered9
- intercepted product prescribing error6
- cystoid macular oedema5
- intraocular pressure increased5
- anaphylactic reaction4
- glaucoma4
- macular oedema4
- uveitis4
- vision blurred4
- ocular hyperaemia3
- refraction disorder3
- cataract operation2
- corneal erosion2
- corneal opacity2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2023 | 12 |
| 2024 | 21 |
| 2025 | 18 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,093 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| refraction disorderSignal | 3 | 3334.5 | 1097.1 | 6,870 |
| intercepted product prescribing errorSignal | 6 | 1450.0 | 674.8 | 7,267 |
| corneal erosion | 2 | 1188.1 | 302.7 | 1,329 |
| cystoid macular oedemaSignal | 5 | 848.0 | 364.6 | 3,416 |
| corneal opacity | 2 | 467.7 | 119.4 | 522 |
| macular oedemaSignal | 4 | 227.6 | 88.0 | 690 |
| intraocular pressure increasedSignal | 5 | 124.7 | 53.7 | 496 |
| cataract operation | 2 | 107.4 | 27.4 | 118 |
| cataractSignal | 20 | 107.1 | 74.3 | 2,002 |
| contraindicated product administeredSignal | 9 | 94.8 | 51.6 | 745 |
| uveitisSignal | 4 | 94.0 | 36.4 | 281 |
| glaucomaSignal | 4 | 66.2 | 25.6 | 196 |
| anaphylactic reactionSignal | 4 | 23.1 | 8.9 | 64 |
| ocular hyperaemiaSignal | 3 | 20.1 | 6.7 | 37 |
| vision blurredSignal | 4 | 9.3 | 3.6 | 22 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.